Fabre-Kramer announces mixed results for depression med

Houston-based Fabre-Kramer Pharmaceuticals has announced positive results for its Phase III studies of Gepirone ER for major depression. Researchers say that one of the studies hit its primary endpoint of reducing symptoms of depression by a statistically significant margin over a placebo. But a second study failed to reach statistical significance.

"Gepirone ER represents the first of a new class of antidepressants, the direct serotonin agonists," said company CEO Stephen J. Kramer. "Working by a new mechanism of action, Gepirone ER, if approved, could provide a new treatment modality for depressed patients who are not helped by currently available treatments."

- read this press release for more

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.